MIAMI, FL–(Marketwired – Nov 14, 2017) – Omni Health, Inc., (OTC PINK: OMHE), a plumb integrated medical association dedicated to a enlargement of pharmaceutical, anti-aging products, and cannabis biotech engineering, now published a minute to a Shareholders. The Letter to Shareholders provides a mid-year corporate update, including new accomplishments in cannabinoid biotechnology and arriving milestones, and is as follows:
Dear Shareholders,
As we pierce into a second entertain (our financial year ends Apr 30th), we can overtly contend that we have never been some-more confident about a opportunities for success. Omni Health’s annual revenues have grown to some-more than $4.6 million; it is with a good clarity of thankfulness and honour in a association that we share my certainty that this success will continue into a future, as we continue to grow and strengthen. we would also like to demonstrate my frank appreciation for your calm with a routine of assiduously enlightening and flourishing a company, a brand, and a network of consultant collaborators. These factors are pushing novel and existent prospects that will position a Company as an emergent, widespread participation in key, remunerative markets.
Omni Health is an well-developed association with an unusual birthright and a earnest future. The stream batch cost does not accurately simulate a benefaction enlargement in prophesy or value; however, indifferent confluence to a core values and prophesy is temperament fruits of swell that will hopefully shortly turn clear in a batch price. To keep a Shareholders sideways of such growth, Omni Health will be updating stream shareholders, and intensity new shareholders, with updates around press releases starting this week.
I am also an Omni Health Shareholder and have privately invested a poignant volume of my possess collateral into a Company. Please rest positive that I’m operative diligently to emanate a cycle of incessant enlargement that over time will certainly outcome in tolerable benefit for all a shareholders. The fulfilment of critical enlargement formulation targeting vital, commerce-friendly environments will outcome in a clever and tolerable business upturn.
I am gay to news that we reached a finish of a prolonged routine that began over 10 months ago, culminating in a several high-profile developments we will shortly be announcing. There have been endless negotiations that we have not talked about publicly, though as we are now in a final stages of these negotiations, we can now pronounce some-more plainly about dual critical developments that will move a Company to a totally new turn of success.
The first, that we can share now, is enlargement in a globe of a cannabinoid-based drug-development. In partnership with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory trail to commercialization of a breakthrough, exclusive devalue representative with a intensity to yield ongoing pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of knowledge building corporate enlargement and profitability with critical idealist leadership. His core competencies embody practicable creation enabling rival enlargement into remunerative niche markets while effectively harmonizing inner medical and healing standards with informal and inhabitant regulatory guidelines. From a laboratory to a handling room, his specialty has always been translational biotherapeutics — evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical enlargement capturing health veteran and consumer self-care markets opposite North America, Europe, Australia and Asia. An expressive and effective multilingual communicator, Dr. Aliffe is also smooth in scholarship and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The tellurian marketplace for pain government will grow from scarcely $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent difficult regulations per a use of opioids and a series of opioid pain drugs being pulled from a marketplace emanate an additional event to fill a blank left by a withdrawal of these drugs. As such, there is a poignant intensity for cannabinoid biotherapeutics to truly seize a day in a diagnosis of ongoing pain and other debilitating conditions.
We are now in negotiations with several private financier groups to lift sufficient collateral for this initiative.
We will continue to yield updates over a entrance weeks that will embody a collaboration/joint try with one of a largest European cannabis companies regarding to a import and placement of breakthrough cannabidiol-centered consumer products that we are currently building for them. The initial stairs in a commercialization routine will engage a investiture of a clever participation in a European market, a advantages of that will be elaborated on in destiny communications.
Again, we appreciate we for your calm and courteously expect your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., (OTC PINK: OMHE) is a 40 year aged plumb integrated medical association dedicated to a enlargement of pharmaceutical, anti-aging products, and cannabis biotech engineering with a strong tube of new products and breakthrough innovation.
Safe Harbor Statement
Any statements contained in this press recover that do not report chronological contribution might consecrate forward-looking statements as that tenure is tangible in a Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are formed on stream expectations, though are theme to a series of risks and uncertainties. The factors that could means tangible destiny formula to differ materially from stream expectations include, though are not singular to, risks and uncertainties relating to a Company’s ability to develop, marketplace and sell products formed on a technology; a approaching advantages and efficiency of a Company’s products and technology; a accessibility of estimable additional appropriation for a Company to continue a operations and to control investigate and development, and destiny product commercialization; and a Company’s business, research, product development, regulatory approval, selling and placement skeleton and strategies.
